Register a trial

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04619303




Registration number
NCT04619303
Ethics application status
Date submitted
27/10/2020
Date registered
6/11/2020

Titles & IDs
Public title
Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO
Scientific title
A Randomized Clinical Trial of Intravitreal dexamethasOne Versus Bevacizumab in Aboriginal and Torres Strait Islander patientS With Diabetic Macular Oedema (The OASIS Study)
Secondary ID [1] 0 0
OASIS
Universal Trial Number (UTN)
Trial acronym
OASIS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetic Macular Edema 0 0
Diabetic Retinopathy 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye
Metabolic and Endocrine 0 0 0 0
Diabetes
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dexamethasone intravitreal implant
Treatment: Drugs - Bevacizumab Injectable Product

Experimental: Dexamethasone Implant - Receive 0.7mg dexamethasone implant (Ozurdex) at baseline visit. Monthly review with repeat administration of intravitreal treatment every three months for DMO and laser as clinically indicated.

Active comparator: Bevacizumab - Receive 1.25mg/0.05ml bevacizumab (Avastin) at baseline visit. Monthly review with repeat administration of intravitreal treatment every one month for DMO and laser as clinically indicated.


Treatment: Drugs: Dexamethasone intravitreal implant
Intravitreal injection of 0.7mg dexamethasone implant

Treatment: Drugs: Bevacizumab Injectable Product
Invtravitreal injection of 1.25mg/0.05mL bevacizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Difference in best corrected visual acuity change between treatment arms
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Best corrected visual acuity loss or gain
Timepoint [1] 0 0
12 months
Secondary outcome [2] 0 0
Change in central macular thickness
Timepoint [2] 0 0
12 months
Secondary outcome [3] 0 0
Number of injections
Timepoint [3] 0 0
12 months
Secondary outcome [4] 0 0
Appointments attended
Timepoint [4] 0 0
12 months
Secondary outcome [5] 0 0
Intraocular pressure change
Timepoint [5] 0 0
12 months
Secondary outcome [6] 0 0
Intraocular pressure elevation
Timepoint [6] 0 0
12 months
Secondary outcome [7] 0 0
Intraocular pressure elevation requiring treatment
Timepoint [7] 0 0
12 months
Secondary outcome [8] 0 0
Adverse Events
Timepoint [8] 0 0
12 months

Eligibility
Key inclusion criteria
Inclusion criteria:

* Self-identifying as Aboriginal Australian or Torres Strait Islander
* Adults aged 18 years and over
* Diagnosis of DM (type 1 or type 2)
* BCVA of at best 0.2 LogMAR (20/32) 6/9 in the study eye
* Pseudophakic, or phakic with significant lens opacity and scheduled to undergo cataract surgery at the time of enrolment
* Presence of any grade of DR with centre-involving DMO, as defined by clinical examination and OCT scan findings

* Active DMO: Centre-involving/threatening DMO, as defined by clinical examination and OCT scan findings.
* At risk of DMO: Patients scheduled for cataract surgery with non-centre involving DMO who are assessed as being at risk of post-operative centre-involving DMO based on clinical examination, OCT scan findings, and Investigator discretion.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

* Intervention: Previous treatment in the study eye including at the time of the first trial treatment with:

* IVT anti-VEGF injections within the last six weeks;
* Macular laser treatment within the last four months;
* IVT triamcinolone or triescence within the last six months; at the time of the first trial treatment.
* History of open-angle glaucoma or steroid-induced IOP elevation that required IOP-lowering treatment or, IOP =25 (Goldmann applanation) on two consecutive clinic visits.
* Eyes with concurrent ocular pathology other than DMO, or a cataract-causing visual loss, including macular ischaemia as determined by clinical examination and FFA imaging.
* Women who are breastfeeding, confirmed as pregnant or planning on becoming pregnant in the next 6-12 months.
* Participants for whom Ozurdex or Avastin treatment are contraindicated as per product information:

* Active or suspected ocular/periocular infections, including most viral diseases of the cornea and conjunctiva, active epithelia herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
* Aphakic eyes with rupture of the posterior lens capsule.
* Eyes with an anterior chamber intraocular lens and rupture of the posterior lens capsule.
* Known angina, myocardial infarction, TIA or CVA in the last three months.
* Known hypersensitivity to any components of these products.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/02/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/02/2020
Sample size
Target
Accrual to date
Final
59
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 0 0
Broome Regional Aboriginal Medical Service - Broome
Recruitment hospital [2] 0 0
Derby Hospital - Derby
Recruitment hospital [3] 0 0
Fitzroy Crossing Hospital - Fitzroy Crossing
Recruitment hospital [4] 0 0
Halls Creek Health Service - Halls Creek
Recruitment hospital [5] 0 0
Bega Garnbirringu Health Service - Kalgoorlie
Recruitment hospital [6] 0 0
Nickol Bay Hospital - Karratha
Recruitment hospital [7] 0 0
Ord Valley Aboriginal Health Service - Kununurra
Recruitment hospital [8] 0 0
Laverton Hospital - Laverton
Recruitment hospital [9] 0 0
Derbarl Yerrigan Health Service Inc. - Perth
Recruitment hospital [10] 0 0
Lions Eye Institute Nedlands - Perth
Recruitment hospital [11] 0 0
Lions Eye Institute Midland - Perth
Recruitment hospital [12] 0 0
Mawarnkarra Health Service - Roebourne
Recruitment hospital [13] 0 0
Wirraka Maya Health Service Aboriginal Corporation - South Hedland
Recruitment postcode(s) [1] 0 0
6725 - Broome
Recruitment postcode(s) [2] 0 0
6728 - Derby
Recruitment postcode(s) [3] 0 0
6728 - Fitzroy Crossing
Recruitment postcode(s) [4] 0 0
6770 - Halls Creek
Recruitment postcode(s) [5] 0 0
6430 - Kalgoorlie
Recruitment postcode(s) [6] 0 0
6714 - Karratha
Recruitment postcode(s) [7] 0 0
6743 - Kununurra
Recruitment postcode(s) [8] 0 0
6440 - Laverton
Recruitment postcode(s) [9] 0 0
6004 - Perth
Recruitment postcode(s) [10] 0 0
6009 - Perth
Recruitment postcode(s) [11] 0 0
6056 - Perth
Recruitment postcode(s) [12] 0 0
6718 - Roebourne
Recruitment postcode(s) [13] 0 0
6722 - South Hedland

Funding & Sponsors
Primary sponsor type
Other
Name
Lions Eye Institute, Perth, Western Australia
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Lions Outback Vision
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Allergan
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Angus Turner, FRANZCO
Address 0 0
Lions Eye Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified individual patient data as well as visit data with primary and secondary outcome data and accompanying data dictionary will be made available.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Analytic code
When will data be available (start and end dates)?
6 months
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04619303